Esperion Therapeutics
ESPR
ESPR
155 hedge funds and large institutions have $1.25B invested in Esperion Therapeutics in 2018 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 51 increasing their positions, 47 reducing their positions, and 25 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
less funds holding
Funds holding: →
4% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 25
9.71% less ownership
Funds ownership: 115.22% → 105.51% (-9.7%)
77% less call options, than puts
Call options by funds: $34.7M | Put options by funds: $151M
Holders
155
Holding in Top 10
4
Calls
$34.7M
Puts
$151M
Top Buyers
| 1 | +$7.77M | |
| 2 | +$6.35M | |
| 3 | +$5.34M | |
| 4 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$4.44M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.43M |
Top Sellers
| 1 | -$21.7M | |
| 2 | -$19.4M | |
| 3 | -$18.1M | |
| 4 |
State Street
Boston,
Massachusetts
|
-$14.6M |
| 5 |
VOYA Investment Management
Atlanta,
Georgia
|
-$12.8M |